Monomeric Phospholamban Overexpression in Transgenic Mouse Hearts
- 1 October 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 81 (4) , 485-492
- https://doi.org/10.1161/01.res.81.4.485
Abstract
Phospholamban, a prominent modulator of the sarcoplasmic reticulum (SR) Ca2+-ATPase activity and basal contractility in the mammalian heart, has been proposed to form pentamers in native SR membranes. However, the monomeric form of phospholamban, which is associated with mutating Cys41 to Phe41, was shown to be as effective as pentameric phospholamban in inhibiting Ca2+ transport in expression systems. To determine whether this monomeric form of phospholamban is also functional in vivo, we generated transgenic mice with cardiac-specific overexpression of the mutant (Cys41→Phe41) phospholamban. Quantitative immunoblotting indicated a 2-fold increase in the cardiac phospholamban protein levels compared with wild-type controls, with ≈50% of phospholamban migrating as monomers and ≈50% as pentamers upon SDS-PAGE. The mutant-phospholamban transgenic hearts were analyzed in parallel with transgenic hearts overexpressing (2-fold) wild-type phospholamban, which migrated as pentamers upon SDS-PAGE. SR Ca2+-uptake assays revealed that the EC50 values for Ca2+ were as follows: 0.32±0.01 μmol/L in hearts overexpressing monomeric phospholamban, 0.49±0.05 μmol/L in hearts overexpressing wild-type phospholamban, and 0.26±0.01 μmol/L in wild-type control mouse hearts. Analysis of cardiomyocyte mechanics and Ca2+ kinetics indicated that the inhibitory effects of mutant-phospholamban overexpression (mt) were less pronounced than those of wild-type phospholamban overexpression (ov) as assessed by depression of the following: (1) shortening fraction (25% mt versus 45% ov), (2) rates of shortening (27% mt versus 48% ov), (3) rates of relengthening (25% mt versus 50% ov), (4) amplitude of the Ca2+ signal (21% mt versus 40% ov), and (5) time for decay of the Ca2+ signal (25% mt versus 106% ov) compared with control (100%) myocytes. The differences in basal cardiac myocyte mechanics and Ca2+ transients among the animal groups overexpressing monomeric or wild-type phospholamban and wild-type control mice were abolished upon isoproterenol stimulation. These findings suggest that pentameric assembly of phospholamban is important for mediating its optimal regulatory effects on myocardial contractility in vivo.Keywords
This publication has 10 references indexed in Scilit:
- Phospholamban Regulates the Ca2+-ATPase through Intramembrane InteractionsJournal of Biological Chemistry, 1996
- Effect of ablation of phospholamban on dynamics of cardiac myocyte contraction and intracellular Ca2+American Journal of Physiology-Cell Physiology, 1996
- A Leucine Zipper Stabilizes the Pentameric Membrane Domain of Phospholamban and Forms a Coiled-coil Pore StructureJournal of Biological Chemistry, 1996
- Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice.Journal of Clinical Investigation, 1996
- Computational searching and mutagenesis suggest a structure for the pentameric transmembrane domain of phospholambanNature Structural & Molecular Biology, 1995
- The hydrophilic domain of phospholamban inhibits the Ca2+ transport step of the Ca2+-ATPaseBiochemical Journal, 1994
- Control of the calcium pump of cardiac sarcoplasmic reticulum. A specific role for the pentameric structure of phospholamban?Cardiovascular Research, 1993
- Expression and Site-specific Mutagenesis of PhospholambanPublished by Elsevier ,1989
- Phospholamban Phosphorylation in Intact VentriclesJournal of Biological Chemistry, 1989
- Regulation of Ca2+ transport by cyclic 3′,5′-AMP-dependent and calcium-calmodulin-dependent phosphorylation of cardiac sarcoplasmic reticulumBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1985